The rapid development of programmable nuclease-based genome editing technologies has enabled targeted gene disruption and correction both in vitro and in vivo. This revolution opens up the possibility of precise genome editing at target genomic sites to modulate gene function in animals and plants. Among several programmable nucleases, the type II clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated nuclease 9 (Cas9) system has progressed remarkably in recent years, leading to its widespread use in research, medicine and biotechnology. In particular, CRISPR-Cas9 shows highly efficient gene editing activity for therapeutic purposes in systems ranging from patient stem cells to animal models. However, the development of therapeutic approaches and delivery methods remains a great challenge for biomedical applications. Herein, we review therapeutic applications that use the CRISPR-Cas9 system and discuss the possibilities and challenges ahead.
Introduction
Nuclease-mediated genome editing offers a powerful tool for gene therapy. Zinc finger nucleases (ZFNs), transcription activator-like effectors and clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated nuclease 9 (Cas9) have been intensively developed as programmable nucleases [1] . Among these nucleases, CRISPR-Cas9 has been the most popular in recent years, opening up a new era in genome editing. CRISPR-Cas9 is derived from the type II adaptive immune system in bacteria and archaea, in which foreign DNA elements derived from plasmids or phages are captured and inserted in the host genome to form a CRISPR locus. This region is transcribed and processed to yield two small RNAs, a target-derived CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA), which are then complexed with the endogenous Cas9 protein. The resulting protein-RNA complex recognizes and cleaves target DNA by the establishment of base pairing between crRNA and the target DNA. For genome editing applications, the crRNA:tracrRNA duplex can be physically linked to make a single-guide RNA (sgRNA) [2] . Contrast to previous nucleases as a genome editing tool, CRISPRCas9 is mediated by 20 nucleotides of guide RNA that recognize the target DNA via Watson-Crick base pairing. Cas9, nuclease guided by guide RNA that contains the 20 nucleotides of complementary target sequence, can generate double-strand breaks (DSBs) at the three nucleotides upstream of the protospacer adjacent motif at the target genome. It simplifies the application of CRISPR-Cas9 tool for genome editing by replacing 20 nucleotides of guide RNA to retarget sequence of interest without Cas9 protein engineering and further allows targeting diverse genomes across broad range of species without complicated design of CRISPR-Cas9 system. These nucleases cleave chromosomal target sites in host cells, producing DNA DSBs, the repair of which by endogenous systems leads to endogenous gene knockouts, gene corrections or targeted insertions of a gene of interest. Homology-directed repair (HDR) and homologous recombination are error-free DSB repair mechanisms that use a template DNA. Non-homologous end joining (NHEJ) is an error-prone repair system that functions without a donor template DNA. NHEJ repair of DSBs results in small insertions and deletions (indels) at nuclease target sites. NHEJ is the preferred system for disruption of target genes, whereas HDR is the better system for gene correction or knock-in.
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To apply CRISPR-Cas9 therapeutically, both the efficacy and safety of specific nucleases must be addressed. Even if CRISPRCas9 shows efficient gene editing in cells, its high activity may result in unexpected side effects such as off-target mutations and cytotoxicity. CRISPR-Cas9 may also elicit host immune responses, limiting its utility in gene therapy. Delivery of CRISPRCas9 in vitro and in vivo is hampered by its large size. Smaller Cas9 orthologs or split forms of Cas9 have been adapted as alternative reagents for efficient delivery [3] [4] [5] . Here, we review several therapeutic applications of CRISPR-Cas9, including antiviral and antibacterial therapies to inhibit infection and gene repair approaches in germ-line cells, stem cells and in vivo disease models, in which several delivery methods have been used in preclinical studies (Figure 1 ). We also address the perspectives of CRISPR-Cas9's therapeutic applications in future directions.
Therapeutic applications

Antiviral therapy
Antiviral genome editing includes inhibition of viral infection or replication. Programmable nuclease-mediated antiviral therapy has become one of the promising new approaches in gene therapy. After successful completion of a phase I clinical trial of a ZFN designed to inhibit human immunodeficiency virus (HIV) infection (ClinicalTrials.gov number: NCT00842634 and NCT01044654), a phase II clinical trial is currently ongoing (ClinicalTrials.gov number: NCT01543152, NCT02225665). This ZFN targets the C-C chemokine receptor type (CCR5) gene, which encodes CCR5, an essential co-receptor of HIV infection. In studies involving CD4þT cells obtained from acquired immune deficiency syndrome (AIDS) patients, T cells devoid of the CCR5 protein are no longer infected by HIV-1. Furthermore, ZFNtreated patients exhibited significant reductions in HIV viral DNA and/or RNA in the blood [6] . However, the CCR5-targeted ZFN can also cleave the CCR2 gene, leading to large deletions [7] . It is unknown whether this and other off-target mutations would cause any side effects. In general, ZFNs have off-target effects and are often cytotoxic [8] . Furthermore, it is technically difficult to design ZFNs with desired target specificity.
Cas9 nucleases have now largely replaced ZFNs, at least in research, in studies designed to prevent viral infection or replication in host cells. Cas9 can target viral genes or host genes that encode essential receptors to suppress infection of viruses including HIV-1, Epstein-Barr virus, hepatitis B virus, human papillomavirus, polyomavirus and herpes simplex virus1 [9] [10] [11] [12] [13] [14] [15] [16] .
The most advanced CRISPR-Cas9-mediated antiviral therapy to date is CCR5 gene knockout in human primary T cells and CD34þ haematopoietic stem and progenitor cells (HSPCs). In fact, CCR5 was one of the first genes in eukaryotic cells targeted by Cas9 [17] . Several efforts to engineer HSPCs have shown promising results ,for example, CRISPR-Cas9 generated indels at the CCR5 target locus at a frequency of 30% in human CD34þ HSPCs [18] . This result was followed by a demonstration of enhancement of CRISPR-Cas9 activity via co-delivery of chemically modified guide RNAs and Cas9 mRNA into primary T cells and CD34þ HSPCs [19] (RNPs) in primary human CD4þT cells [20] . Cas9 RNPs led to the loss of CXCR4 expression in up to $40% of CD4þT cells. These approaches hold powerful potential of the CRISPR-Cas9 in ex vivo cell therapy by modifying patient cells using CRISPR-Cas9 system and transplant gene-edited cells back to the patient. These modified T cells would not be infected by HIV virus, leading to expansion of HIV-resistant T cell populations in the patient. Several other antiviral approaches with great potential in infectious disease therapy involved directly targeting viral genomes with CRISPR-Cas9 and demonstrate the feasibility of inhibiting viral replication without affecting the human genome [9] [10] [11] [12] [13] [14] . However, this approach can be limited by the generation of resistant viruses with mutations that escape CRISPR-Cas9-guided gene knockout. Indeed, a lentiviral vector expressing Cas9 and an antiviral sgRNA inhibited HIV replication for only a short period. Moreover, HIV escape has been reported with reamplification of these mutant viruses to a form that is not affected by CRISPR-Cas9 [21] . It is crucial to target several essential viral genes with highly active CRISPR-Cas9 for complete viral clearance in human cells. Complete removal of latent form of virus within the host genome could avoid the re-emergence of virus. Using CRISPR-Cas9 system to target both 5 0 long terminal repeat (LTR) LTR and 3 0 LTR of proviral genome of HIV-1, this integrated proviral DNA was excised from the host chromosome [22] .
Removal of pathological bacteria
CRISPR-Cas9 nucleases that target bacterial genes and thereby inhibit bacterial growth can be used as antibacterial reagents [23] [24] [25] [26] [27] . In such studies, DNA encoding CRISPR-Cas9 targeted to antibiotic-resistant genes in pathological bacteria is delivered to cells via bacteriophages. In a proof of principle study, mouse skin infected with a Staphylococcus aureus bacterial strain was treated with CRISPR-Cas9-encoding phage, resulting in loss of bacteria from the skin [23] .This study certainly shows the potential of Cas9-based antibacterial therapy in human bacterial diseases. Moreover, it has the advantage of only disrupting bacterial genes without targeting the human genome because this bacterial sequence does not exist in the host.
Correction of disease-causing gene mutations
In the context of gene therapy, CRISPR-Cas9 seems to be an attractive, highly specific tool for correcting disease-causing mutations. CRISPR-Cas9-mediated NHEJ machinery could disrupt genes by introducing indels. This NHEJ repair machinery could also be used to excise exons and reframe the disrupted reading frame in the case of frameshift mutations. On the other hand, in the presence of an oligodeoxynucleotide (ODN) template, mutations could be corrected precisely via the HDR repair machinery, which would replace the mutated sequence with the ODN sequence.
The CRISPR-Cas9 system has been tested in in vitro and in vivo models of a number of genetic diseases, including cataracts, Duchenne muscular dystrophy (DMD), a1-antitrypsindeficiency, b-thalassaemia, cystic fibrosis (CF), haemophilia, hyperammonemia, hearing loss, limb-girdle muscular dystrophy, myeloproliferative disorders, severe combined immunodeficiency (SCID) and tyrosinemia, resulting in NHEJ or HDRmediated gene repair. These results suggest the therapeutic potential of the CRISPR-Cas9 system (Table 1) .
CRISPR-Cas9 can be delivered via viral vehicles or as an RNP complex of Cas9 protein and guide RNA with high efficacy [49, 50] . Application of Cas9 RNP has a certain benefit of rapid degradation in cells within 24 h by endogenous proteases and ribonucleases without concern of integration into the host genome, reducing off-target effects [50] . However, there is a challenge to deliver Cas9 RNP in vivo with limited delivery efficacy. Use of non-integrating viral vector vehicles could overcome the delivery issue in vivo.
Germ-line therapy
The first proof of principle study to demonstrate germ-line genome editing via CRISPR-Cas9 involved correction of DMDcausing mutations in a mouse zygote. DMD, a life-threatening muscle-wasting disease that significantly shortens life expectancy, is caused by mutations in the dystrophin gene that result in complete loss of dystrophin protein expression in muscles. Through its interaction with the dystrophin-associated complex, this protein provides stability to the muscle cell. A lack of dystrophin causes severe muscle damage, resulting in muscle necrosis. Several clinical trials for DMD are currently ongoing, including a phase III clinical trial (ClinicalTrials.gov number: NCT02255552) that is testing oligonucleotide-mediated exon skipping. In addition, a phase I trial (ClinicalTrials.gov number: NCT00428935) of micro-dystrophin gene delivery via an adenoassociated virus (AAV) vector has been completed [51] . Yet, these approaches were only associated with limited clinical outcomes [52, 53] .
To evaluate the efficacy of CRISPR-Cas9 in germ-line gene therapy, Cas9 protein, sgRNA and an ODN template were codelivered into dystrophic mdx mouse embryos. Microinjection of these components into the cytoplasm or pronuclei of zygotes restored dystrophin protein expression as a result of successful HDR-mediated gene repair that corrected the diseaseassociated nonsense mutation in exon 23 of the dystrophin gene [29] . However, gene-corrected mice showed mosaicism, such that 2-100% corrected dystrophin gene. It is speculated that mosaicism occurs as a result of gene correction in embryonic cells after the zygote stage. Gene-corrected mdx mice showed complete rescue of dystrophin protein levels at the sarcolemma of mdx muscles in mice with 41% of the mdx alleles corrected via HDR or with 83% corrected via NHEJ. This study highlights that gene repair in all cells is not prerequisite for wild-type phenotype restoration. It implies the potential value of germ-line therapy using CRISPR-Cas9.
Germ-line gene modification also emphasizes the potential for transmission of such altered genes to the progeny of modified organisms, as seen in studies of cataract mice. Correction of the disease-associated mutant Crygc alleles was shown following co-delivery of Cas9 mRNA, sgRNA and an ODN template to mutant mouse zygotes. The mice developed with a normal eye phenotype: black lenses as compared with the cloudy control lenses in cataract mice [28] . In addition, the repaired Crygc gene was successfully transmitted to the offspring of these mice, demonstrating the feasibility of transmitting alleles modified via Cas9-mediated genome editing.
Patient-derived cell therapy
Patient-derived induced pluripotent stem (iPS) cells have been intensively investigated for therapeutic approaches, ever since four factors were reported by the Takahashi and Yamanaka team in 2006 to reprogram cells [54] . Nonetheless, human iPSs have been difficult to manipulate and even more difficult to convert into functional organs following differentiation. Several patient-derived iPS cell lines have been engineered with relative ease via CRISPR-Cas9 to repair disease-causing mutations, differentiated and then transplanted into the appropriate organ in an animal model, leading to functional rescue [30] [31] [32] [33] [34] [35] [36] [38] [39] [40] [41] . We recently demonstrated this approach for treatment of haemophilia A, caused by deficiency of coagulation factor VIII, which leads to excessive internal or external bleeding. A patient-derived iPS cell line harbouring a chromosomal inversion mutation in the factor 8 (F8) gene was repaired via delivery of an RNP complex of Cas9 and dual sgRNAs that targeted two different sites to induce reinversion of the mutation [38] . Endothelial cells differentiated from inversion-corrected iPS cells were then transplanted into haemophiliac mice, leading to partial rescue of the F8 deficiency and a significant increase in survival time. These differentiated iPS-derived cells could functionally interact with other cells in the target organ. This study supports the potential of ex vivo therapy using Cas9-modified differentiated patient-derived iPS cells.
The ex vivo gene editing approach has also been demonstrated for DMD therapy. Several researchers have reported successful correction of the disease-causing mutations in DMD patient-derived iPS cells via either the HDR repair machinery [34, 36] or NHEJ machinery [35] . The most common mutations in DMD are deletions of several exons that disrupt the reading frame; the hot spot for these mutations is located between exons 45-55 in the dystrophin gene. The CRISPR-Cas9 system was applied to induce large gene deletions to remove the mutation hot spot in human DMD patient-derived iPS cells. These deletions (exons 45-55) of up to 725 kb and NHEJ resulted in restoration of the disrupted dystrophin reading frame in several human DMD-derived iPS cells harbouring gene deletions or duplication mutations [35] . These repaired iPS cells were differentiated into cardiomyocytes or skeletal myotubes with successful engraftment into tibialis anterior muscles of non-obese diabetic (NOD)/NOD scid IL2Rgamma-mdx mice. The symptoms were reduced to a mild Becker muscular dystrophy-like phenotype. This approach may have great potential for treating $60% of the DMD population [37] . iPS cell correction and restoration of function have also been demonstrated for CF, the most common chronic disease of the lung. CF is caused by mutations in the cystic fibrosis transmembrane receptor (CFTR) gene, which encodes a chloride transporter. The disease affects not only the lung but also organs in the digestive system, including the pancreas, intestine, liver and kidney, because of CFTR function in mucus-producing cells. Disease severity varies; shortened life expectancy occurs mainly because of premature respiratory failure. To demonstrate the potential of CRISPR-Cas9 in CF therapy, two plasmids expressing Cas9 and sgRNA were co- [47, 48] delivered into patient-derived iPS cells harbouring a homozygous deletion of F508 in the CFTR gene, causing a phenylalanine deletion at position 508 in the protein [33] . Repaired iPS cells were then differentiated into mature airway epithelial cells with recovery of CFTR expression, resulting in improved chloride current in response to stimulation, measured by patchclamp electrophysiology, relative to uncorrected cells. The CRISPR-Cas9 system could also be used to treat hereditary deafness or hearing loss. Mutations in the MYO15A gene, which is required for the proper development of sensory hair cells in the inner ear, are associated with hearing loss. iPS cells derived from patients carrying MYO15A mutations were found to exhibit abnormal morphology and function after differentiation into hair cell-like cells. These defects in differentiated cells were rescued following CRISPR-Cas9 and ODN delivery into patient-derived iPS cells. Voltage-dependent currents and current densities were restored and similar to those of wild-type hair-like cells, as measured by electrophysiological recordings [39] .
Gene therapy in animal models of human genetic diseases CRISPR-Cas9 technology can be used to correct disease phenotypes in animal models via systemic delivery or direct delivery into target organs. The first proof of principle study of this approach was in a mouse model of tyrosinemia [47] . Patients with tyrosinemia type I have a severe defect in tyrosine catabolism, caused by a deficiency in fumarylacetoacetate hydrolase (FAH), that results in the accumulation of toxic metabolites and liver dysfunction. FAH null mice harbour a homozygous G!A point mutation in the last nucleotide of FAH exon 8 that causes skipping of this exon during splicing. Two plasmids expressing Cas9 and sgRNA were co-delivered with a donor template plasmid via hydrodynamic tail vein injection, which results in a high level of FAH expression in the liver [47] . The FAH gene was corrected with an indel frequency of $0.4% to induce inclusion of exon 8 in the FAH transcript, resulting in 33.5% FAHþ cells in the liver and, consequently, rescue of the loss of body weight. This study demonstrates the feasibility of in vivo CRISPR-Cas9 genome editing. However, this delivery method would probably not be applicable in the clinic because of the potential for liver damage following systemic delivery of a large volume of such reagents.
AAV is an attractive vehicle for efficient, safe transgene delivery in vivo. Numerous independent clinical trials have shown the therapeutic potential of AAV-mediated gene therapy. As the first demonstration of using AAV to deliver CRISPR-Cas9 in vivo, two AAV vectors, one expressing Cas9 derived from Streptococcus pyogenes and the other expressing sgRNA, were administrated into mouse neurons, immune cells and endothelial cells to knockout multiple genes [55, 56] . Because of the limited packaging capacity of AAV (<4.7 kb), the use of smaller Cas9 orthologs improves delivery efficiency. A smaller Cas9 ortholog derived from S. aureus has been used; its small size enables the sgRNA-expressing cassette to be packaged into the same AAV vector. A single AAV serotype 8 vector, which has relatively high affinity for hepatocytes, expressing both S. aureus Cas9 and a sgRNA targeting a gene involved in cholesterol regulation, proprotein convertase subtilisin/kexin type 9 (Pcsk9), was administrated to wild-type C57BL/6 mice via tail vein injection [5] . One week after AAV injection, mutation frequencies of 40% were observed in this gene in the mouse liver, with $95% reduction in Pcsk9 levels and $40% reduction in total cholesterol levels in the blood. This study provides evidence for the potential of AAV-mediated Cas9 delivery for efficient gene knockout to lower cholesterol levels in an animal model.
Targeted gene therapy via AAV-mediated delivery of CRISPR-Cas9 may also have potential for correcting diseasecausing mutations. Gene repair using two AAV vectors was demonstrated in the context of hyperammonemia, a condition caused by an X-linked deficiency of the ornithine transcarbamylase (OTC) enzyme, resulting in ammonia accumulation in the blood. Symptoms of this disease include liver damage due to the toxicity of excessive ammonia and developmental delay. Two AAV vectors, one expressing S. aureus Cas9 and the other expressing a guide RNA and the donor DNA, were co-delivered into postnatal mice with a partial deficiency in OTC [46] . As a result, the mutation was corrected in 10% of hepatocytes and survival improved in mice when they were fed a high-protein diet, which makes the condition worse. More recently, co-delivery of lipid nanoparticle-coated S. pyogenes Cas9 mRNA coupled with an AAV vector carrying sequences expressing a sgRNA as well as a donor template resulted in efficient gene correction of a FAH splicing mutation in mouse hepatocytes [48] . In vivo DMD correction using AAV-encoding CRISPR-Cas9 has been demonstrated in several studies [34, [43] [44] [45] . Intramuscular or systemic delivery of S. aureus Cas9 coupled with a pair of guide RNAs via two AAV serotype 9 vectors resulted in partial restoration of dystrophin protein in myofibres, cardiomyocytes and muscle stem cells [34] . Specific force was increased in muscles treated with AAV-expressing S. aureus Cas9 as compared with the contralateral muscle group, yet it was not restored to wild-type levels. AAV has also been used to target cardiac muscles in DMD. Improvement of cardiac muscle function was demonstrated following systemic delivery of dual AAV serotype 8 vectors expressing S. aureus Cas9 and sgRNA. It is interesting to see that very low mutation frequencies (<3%) resulted in 59% of dystrophin transcripts [43] .
AAV vectors can also be delivered into neonatal animals, providing the possibility of gene therapy at the postnatal stage. Two AAV serotype 9 vectors, which are muscle-tropic, were used to deliver S. pyogenes Cas9, sgRNA and donor template sequences into postnatal mdx mice via intraperitoneal injection at day 1, intramuscular injection at P12 or retro-orbital injection at the P18 stage. Each method improved muscle function; the dystrophin protein was expressed and interacted with the dystrophin-associated protein complex in muscles [44] . This HDR-mediated genome editing in postnatal tissues suggests an alternative strategy to overcome the issues of relatively ineffective HDR at later developmental stages, such as postmitotic adult tissues [57] .
Adenovirus (Ad) can be used as a therapeutic vehicle to deliver both S. pyogenes Cas9 and sgRNA sequences in a single vector system. Using this delivery system, the Pcsk9 gene was targeted, resulting in a mutation frequency of $50% in the liver of wild-type C57BL/6 mice and a 35-40% reduction of low density lipoprotein (LDL) cholesterol levels in the blood compared with the control groups at 4 days after administration without any evidence of inflammation [42] . The efficacy of adenovirus expressing CRISPR-Cas9 has also been demonstrated in humanized mice. Human hepatocyte-bearing mice were treated with adenovirus encoding S. pyogenes Cas9 and sgRNA in a single vector, resulting in mutations in human Pcsk9 genes in the chimeric liver and, subsequently, reduced blood levels of human Pcsk9 protein [58] . This approach suggests the possibility of treating several cardiovascular diseases by CRISPR-Cas9-mediated reduction of LDL cholesterol levels.
Challenges and future perspectives
Tremendous advances in the use of CRISPR-Cas9 demonstrate the potential utility of this genome-editing tool in gene or cell therapy. Genome editing has become more precise and offtarget nuclease activity has been reduced. Optimized delivery methods have made CRISPR-Cas9 applicable to genome editing in systems ranging from patient stem cells to animal models in recent few years. More recently, cancer patients' T cell Safety Trial using the CRISPR-Cas has been approved by an advisory committee at the US National Institute of Health. In this trial, CRISPR-Cas will disrupt the genes encoding programmed death-1 and T-cell receptor to enhance antitumor effects (doi:10.1038/ nature.2016.20137). It may initiate the new era for CRISPR-Cas in therapeutic applications.
There are several concerns about the safety and efficacy of the CRISPR-Cas9 system. The toxicity and immunogenicity of bacterial Cas9 and guide RNA must be investigated in large animal models following repetitive exposure of Cas9 and its sgRNA along with investigation of potential off-target nuclease activity following a long period. Moreover, current approaches only incompletely rescue disease phenotypes. Mosaicism in embryos following germ-line gene editing is a primary issue to overcome. Off-target nuclease activity in the genome should be carefully considered. Several groups have developed methods to measure off-target effects. We recently reported an unbiased, highly sensitive whole-genome analysis method, Digenome-sequencing, to measure off-target effects [59, 60] ; we have also reviewed several other methods [61] . Improvement of the delivery and specificity of the CRISPR-Cas9 system could overcome current challenges, allowing this technology to be used therapeutically. In the context of gene therapy, it is favourable to use viral vectors as a vehicle to deliver CRISPR-Cas9 system in vivo. In particular, AAV serotypes (serotype 1-9) retain variable tropism after systemic delivery [62] . Therefore, the use of appropriate AAV serotype could modulate the distribution of CRISPR-Cas into target organs. To further enhance specificity of the CRISPRCas9, HDR-mediated precise correction in the presence of a donor template is favourable. Several studies have reported methods to control the repair mechanism used, to facilitate HDR over NHEJ repair using chemicals [63] and thereby avoid NHEJ-mediated indels, which could cause further detrimental mutations at the on-target site. Several studies have demonstrated the utility of CRISPR-Cas9 in animal models. However, there are limitations to our ability to test the efficacy of guide RNAs in vivo if the sequence is human specific. There are a few humanized mouse models that harbour human genes, including those encoding apolipoprotein A1, CD4/CCR5/cyclin T1, interleukin4 and dystrophin, in the mouse genome [64] [65] [66] [67] . Humanized mouse models can be used to validate the efficacy and safety of human sequence-specific CRISPR-Cas9 systems in vivo for therapeutic purposes. Targeting disease-causing mutations in human transgenic animal models could facilitate moving towards applying this system in clinical trials. Apart from validating the system in vivo, disease modelling using CRISPR-Cas9 could be another platform to identify gene function and mimic human disease genotypes/phenotypes because CRISPR-Cas9 can precisely induce sequence-specific mutations at target sites. Indeed, CRISPR-Cas9 has been used to model human diseases in several species, including mouse, rat, pig, monkey and zebrafish [68] . There is also therapeutic potential of the CRISPR-Cas9 to treat polygenic diseases such as cancers by delivering several sgRNA targeting multiple oncogenes. It is remarkable that this system provides not only a powerful tool for gene therapy purposes but also for identifying the relationship between genetic mutations and disease progression. Taken together, these exciting developments in research, in conjunction with work to overcome current challenges, should move the CRISPR-Cas9 system into clinical applications in the foreseeable future.
Key Points
• The CRISPR-Cas9 system shows highly efficient gene editing activity in therapeutic applications.
• CRISPR-Cas9 can be used as an antiviral or antimicrobial reagent to inhibit infection or disrupt the viral or bacterial genome.
• Disease-causing mutations can be precisely repaired via the CRISPR-Cas9 system.
